drugset / Trial / NCT04508530

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

NCT04508530

Phase 3 Completed 71 enrolled Octapharma
RandomizedCrossoverQuadruple-blindTreatment

Summary

A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome

Timeline

Start
2021-06-30
Primary completion
2024-08-27
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 10 % Intravenous